The investigational cancer drug KOS-862 does not appear to suppress the production of red blood cells and platelets in patients already treated in an ongoing phase I trial, Kosan Biosciences Inc. reported on Wednesday
However, the drug was associated with fatigue, nausea/vomiting, mild peripheral neuropathy and transient cognitive abnormalities, the company said
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!